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induces additional damage to the myocardium, known as reperfusion injury. As a result, the damage inflicted on the myocardium during an STEMI is better defined as ischemia/reperfusion (I/R) injury, the result of ischemic and reperfusion processes.
Myocardial I/R injury is a complex phenomenon involving many players, all contributing to the final damage inflicted on the heart (Central Illustration).
In the present review, we describe the evolving therapies for the treatment of myocardial I/R injury.
These include therapies targeting both ischemic and reperfusion damage. To explain the rationale for the quest for new and better therapies, we describe the pathophysiology of myocardial I/R injury and the translational path of research, from the pre-clinical discovery phase, through proof-of-concept clinical trials, to large trials aimed at changing clinical practice. In the context of this paper, the term myocardial infarction always refers to STEMI.
IMPACT OF STEMI IN 2015:
A PARADIGM SHIFT The incidence of STEMI in Western countries has declined during the last decades due to the progressive implementation of preventive therapies and better control of risk factors (1) . Despite the progressive and gradual decrease in its incidence, STEMI remains a significant health problem, representing a major contributor to mortality/morbidity worldwide (1) . As detailed later in this review, the implementation of timely reperfusion has resulted in a very significant reduction in the acute mortality associated with STEMI. Risk-adjusted in-hospital mortality has decreased from z20% in the late 1980s to z5% among STEMI patients treated in routine practice in 2008 (2) , reaching a plateau thereafter (3) . However, these impressive reductions in mortality rates, resulting from the widespread use of reperfusion strategies and adjuvant pharmacological therapies, have resulted in an increase in the incidence of chronic heart failure.
Although this outcome might at first seem paradoxical, the explanation is simple: patients with a severely depressed cardiac function would not have survived JACC VOL. 65, NO. 14, 2015 Ibáñez et al.
Evolving Therapies for Myocardial I/R Injury the acute STEMI phase in the past, but with the advent of reperfusion, they now survive the index episode and live with a significantly damaged heart (2) . In fact, STEMI is 1 of the major contributors to chronic heart failure.
Post-infarction reduced left ventricular ejection fraction (LVEF) is 1 of the principal causes of chronic heart failure worldwide (4) .
The great success of reperfusion therapies has resulted in a paradigm shift in clinical research in the field of STEMI: attention is no longer solely aimed toward reducing mortality (already very low), but increasingly, is to tackle the downstream consequence of improved survival: post-infarction heart failure.
Successful clinical research has led to interventions for chronic heart failure (drugs and devices) that reduce long-term mortality in STEMI survivors with low LVEF (5) . However, these strategies are economically costly, precluding their universal implementation (6) . Chronic treatment of heart failure represents a huge socioeconomic burden on individuals and health care systems. As explained later in this paper, infarct size is the main determinant of adverse post-infarction outcomes, including heart failure (7) . Therapies able to reduce infarct size are, therefore, urgently sought under the hypothesis that smaller infarctions will result in better long-term heart performance and that this will translate into fewer adverse clinical events (8, 9) . As we detail throughout this paper, the identification of refined or new therapies better able to reduce infarct size is a major challenge to 21st century society.
PATHOPHYSIOLOGY OF I/R INJURY
GENERAL CONSIDERATIONS. After the occlusion of an epicardial coronary artery, the myocardium previously perfused by the occluded artery is in jeopardy.
The hypoperfused myocardial zone during myocardial infarction is known as the area at risk (AAR). If the coronary artery is not rapidly reperfused and no collateral circulation is present, most of the AAR becomes necrotic. Given that many patients receive timely reperfusion therapy, part of the AAR remains free of necrosis: the so-called salvaged myocardium.
The typical morphological features of reperfused myocardial infarction are contraction bands, karyolysis, mitochondrial swelling and disruption, and membrane disruption in cardiomyocytes, accompanied by microvascular destruction, interstitial hemorrhage, and inflammation (10, 11) . Experimental studies identified the determinants of myocardial infarct size as: 1) the size of the AAR (12); 2) the duration of myocardial ischemia (13, 14) ; 3) the amount of residual blood flow through collaterals (12,13); 4) the temperature of the tissue during ischemia; and 5) the hemodynamic situation during ischemia (15) .
The most notable hemodynamic parameter is heart rate, which determines not only myocardial demand, but also coronary blood flow (16); however, hemodynamics influence infarct size only to a limited degree, and infarct size is, thus, largely determined by lack of blood/energy supply and less by myocardial demand, which is significantly reduced by the regional lack of contraction (17) (21) . Although the contribution of reperfusion injury to final infarct size has been disputed in the past, today it is accepted that reperfusion can induce additional damage to the myocardium. This view is supported by strong evidence that interventions applied at the end of the ischemic period (i.e., coinciding with reperfusion) can reduce infarct size. It was already recognized in the mid-1980s that gentle reperfusion at low pressure resulted in significantly less edema and a smaller infarct size than standard abrupt reperfusion at normal pressure (22) . This idea was later developed by Zhao et al. (23) , who demonstrated reduction of infarct size by brief episodes of coronary reocclusion/ reflow at the time of reperfusion, a strategy called ischemic post-conditioning (24) . Because these interventions are applied at the end of the ischemic period, they cannot reduce infarct size by reducing ischemic damage and, thus, must reduce reperfusionrelated damage. From these observations it is clear not only that reperfusion injury contributes to infarct size, but also that all conditioning strategies that protect the myocardium and reduce infarct size act only in conjunction with eventual reperfusion (8, 25, 26) . Evolving Therapies for Myocardial I/R Injury A P R I L 1 4 , 2 0 1 5 : 1 4 5 4 -7 1 efficiently and rapidly the blood flow is restored to the epicardial artery, if there is a microvascular obstruction (MVO) the myocardial tissue will remain without efficient perfusion. MVO (also termed the noreflow phenomenon) during I/R is a major contributor to final infarct size and is an independent predictor of morbidity/mortality (27) . The no-reflow phenomenon was first characterized by Kloner et al. (11, 28) in dogs subjected to 90 min of coronary occlusion and subsequent reperfusion; the coronary microcirculation of these animals showed severe capillary damage, notably swollen and ruptured endothelial cells, and intraluminal thrombosis, and was surrounded by swollen and irreversibly injured cardiomyocytes. In the clinic, the no-reflow phenomenon is seen in 10% to 30% of patients with reperfused STEMI (29, 30) despite successful recanalization of the epicardial coronary arteries; MVO in these patients is detected angiographically from slow or no reflow of contrast medium or by cardiac magnetic resonance (CMR).
MVO develops within minutes of established reperfusion (31, 32) and persists for at least 1 week (33, 34) .
MVO is usually confined to the infarcted myocardium (14, 28) ; however, the existence of no-reflow phenomena within the AAR but outside the infarcted area has not been systematically excluded. Notably, MVO can impair the washout of reduction equivalents and dehydrogenases that is mandatory for valid delineation of infarcted tissue by TTC staining, thus contributing to underestimation of infarct size (35) .
Reduced coronary blood flow is also observed outside of the AAR, but this does not reflect a no-reflow phenomenon, and is instead the result of reflexmediated alpha-adrenergic coronary vasoconstriction (36) (37) (38) . Ibáñez et al.
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Evolving Therapies for Myocardial I/R Injury normalization of the acidic pH also activates calpain, which digests the cytoskeleton and the sarcolemma (53) . The high cytosolic concentrations of Na þ and Ca þþ result in intracellular edema when extracellular osmolarity is rapidly normalized by reperfusion.
Finally, excess formation of reactive oxygen species contributes to sarcolemmal disruption (54). Necrosis is typically followed by an inflammatory response.
Unlike necrosis, apoptosis, autophagy, and necroptosis are regulated processes with specific underlying signal transduction mechanisms (55, 56) . Plaque debris and platelet/neutrophil aggregates can induce a mechanical obstruction of the microcirculation precluding efficient tissue perfusion. The generation of tissue edema following reperfusion can result in external compression of the microcirculation, reducing the perfusion capacity of the capillary network (double arrows). Finally, the microcirculation can disintegrate due to the previous damage and allow the leakiness of circulating cells into the interstitial space. 4. Red blood cell deposits (hemorrhage) are especially harmful due to the release of iron, contributing to the subsequent inflammatory reaction. 5. Cardiomyocytes that have survived the ischemic phase suffer during the reperfusion period due to several intracellular pathways triggered at reperfusion (see text for detailed information about these processes).
6. After the entire ischemia/reperfusion insult has passed, the significant infiltration of myocardial tissue by inflammatory cells can induce an additional damage to the myocardium.
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Ibáñez et al. But, translation of results is highly limited because of their high heart rate (an order of magnitude higher than that of humans) and the small size of their hearts, which ensures that, during permanent coronary occlusion, the inner myocardial layers continue to be served with oxygen and nutrients by diffusion.
Thus, infarction in mice develops within 45 to 90 min (77, 78) , but no more than 70% of the AAR is infarcted even with permanent coronary occlusion (79) .
Rodents generally have a higher heart rate than larger mammals, but whereas rats and rabbits have little first demonstrated the existence of myocardial salvage by reperfusion at 3 h after coronary occlusion ("time is muscle"). Another revolution in the search for improved therapies to reduce the ischemic damage associated JACC VOL. 65, NO. 14, 2015
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A Some of the most relevant landmarks in the quest for therapies to reduce ischemic-(top, blue) and reperfusion-related (bottom, green) injuries are represented. Landmarks chosen represent those with a greater effect on clinical practice (there are many other mechanistic landmarks not represented in the figure because they have not yet reached the clinical arena). As suggested by the gray arrow, during the early years of this quest against ischemia/reperfusion injury, most of the efforts and discoveries were in the ischemic-injury side. In the last decades, and after the ischemic damage was very well approached by clinically available therapies, reperfusion injury therapies have started to arise. The proof-ofconcept era for therapies targeting ischemic injury was in the 1970s, and the large trials arose in the 1980s. For reperfusion injury-targeting therapies, the proof-of-concept era was in the late 1990s and 2000s, and it is expected that large trials testing the effect of therapies to reduce reperfusion injury will be undertaken in the 2010s. Evolving Therapies for Myocardial I/R Injury The combined endpoint will be all-cause mortality or heart failure at 2 years.
Another form of myocardial conditioning well described in animal models is remote ischemic conditioning: conditioning performed in a distant organ (119) . Remote ischemic conditioning is reviewed in detail elsewhere (120) . For the purpose of this review, it is important to mention that remote ischemic pre- However, treatment of patients in the COMMIT trial was not optimal according to current guidelines.
First, STEMI patients received thrombolytic therapy JACC VOL. 65, NO. 14, 2015
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